Vaxcyte, Inc. Common Stock insider trading
PCVXfinancial statementsForm 4 filings on EDGAR258 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at Vaxcyte, Inc. Common Stock bought $0 of stock in the open market, and 2 sold $4M. Officers and directors accounted for $0 of purchases and $4M of sales. The last reported transaction was an option exercise by Wassil Jim on October 5, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 7, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $4MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
258 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | option exercise | 18,000 | $5.35 | $96K | 163,435 | Oct 7, 2026 |
| Oct 5, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | open-market sale10b5-1 | 18,000 | $86.74 | $2M | 145,435 | Oct 7, 2026 |
| Oct 5, 2026 | Cowan Elvia | SVP, Finance & CAO | option exercise | 19,000 | $25.92 | $492K | 46,860 | Oct 7, 2026 |
| Oct 5, 2026 | Cowan Elvia | SVP, Finance & CAO | open-market sale10b5-1 | 19,000 | $86.74 | $2M | 27,860 | Oct 7, 2026 |
| Oct 1, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | option exercise | 2,250 | $5.35 | $12K | 147,685 | Oct 2, 2026 |
| Oct 1, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | open-market sale10b5-1 | 2,155 | $56.65 | $122K | 145,530 | Oct 2, 2026 |
| Oct 1, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | open-market sale10b5-1 | 95 | $57.09 | $5K | 145,435 | Oct 2, 2026 |
| Sep 9, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | open-market sale | 1,334 | $59.52 | $79K | 145,435 | Sep 9, 2026 |
| Sep 8, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | tax withholding | 17,056 | $60.36 | $1M | 429,902 | Sep 9, 2026 |
| Sep 8, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | tax withholding | 7,155 | $60.36 | $432K | 95,316 | Sep 9, 2026 |
| Sep 8, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | tax withholding | 7,651 | $60.36 | $462K | 68,085 | Sep 9, 2026 |
| Sep 8, 2026 | Cowan Elvia | SVP, Finance & CAO | tax withholding | 1,327 | $60.36 | $80K | 27,860 | Sep 9, 2026 |
| Sep 8, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | tax withholding | 5,459 | $60.36 | $330K | 146,769 | Sep 9, 2026 |
| Sep 4, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | open-market sale | 1,381 | $61.16 | $84K | 152,228 | Sep 9, 2026 |
| Sep 4, 2026 | Jodar Luis | Chief Medical Officer | award | 52,632 | $0.00 | — | 52,632 | Sep 9, 2026 |
| Sep 2, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | tax withholding | 1,432 | $61.58 | $88K | 153,609 | Sep 2, 2026 |
| Sep 2, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | tax withholding | 3,427 | $61.58 | $211K | 446,958 | Sep 2, 2026 |
| Sep 2, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | tax withholding | 1,432 | $61.58 | $88K | 102,471 | Sep 2, 2026 |
| Sep 2, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | tax withholding | 659 | $61.58 | $41K | 75,736 | Sep 2, 2026 |
| Sep 2, 2026 | Cowan Elvia | SVP, Finance & CAO | tax withholding | 326 | $61.58 | $20K | 29,187 | Sep 2, 2026 |
| Sep 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | option exercise | 2,250 | $5.35 | $12K | 158,518 | Sep 2, 2026 |
| Sep 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale | 1,537 | $60.89 | $94K | 156,981 | Sep 2, 2026 |
| Sep 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale | 713 | $61.48 | $44K | 156,268 | Sep 2, 2026 |
| Sep 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale | 924 | $60.95 | $56K | 155,344 | Sep 2, 2026 |
| Sep 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale | 303 | $61.42 | $19K | 155,041 | Sep 2, 2026 |
| Aug 31, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | tax withholding | 1,273 | $60.74 | $77K | 156,268 | Sep 2, 2026 |
| Aug 31, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | tax withholding | 2,862 | $60.74 | $174K | 450,385 | Sep 2, 2026 |
| Aug 31, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | tax withholding | 1,273 | $60.74 | $77K | 103,903 | Sep 2, 2026 |
| Aug 31, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | tax withholding | 361 | $60.74 | $22K | 76,395 | Sep 2, 2026 |
| Aug 31, 2026 | Cowan Elvia | SVP, Finance & CAO | tax withholding | 243 | $60.74 | $15K | 29,513 | Sep 2, 2026 |
| Aug 5, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | option exercise | 17,000 | $24.79 | $421K | 93,756 | Aug 5, 2026 |
| Aug 5, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | open-market sale10b5-1 | 17,000 | $55.00 | $935K | 76,756 | Aug 5, 2026 |
| Aug 3, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | option exercise | 2,250 | $5.35 | $12K | 159,791 | Aug 5, 2026 |
| Aug 3, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale10b5-1 | 861 | $53.50 | $46K | 158,930 | Aug 5, 2026 |
| Aug 3, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale10b5-1 | 1,389 | $54.09 | $75K | 157,541 | Aug 5, 2026 |
| Aug 3, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | option exercise | 10,000 | $5.35 | $54K | 115,176 | Aug 5, 2026 |
| Aug 3, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | open-market sale10b5-1 | 6,956 | $53.76 | $374K | 108,220 | Aug 5, 2026 |
| Aug 3, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | open-market sale10b5-1 | 3,044 | $54.18 | $165K | 105,176 | Aug 5, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | option exercise | 16,198 | $2.03 | $33K | 469,445 | Jul 28, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | open-market sale10b5-1 | 11,783 | $55.52 | $654K | 457,662 | Jul 28, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | open-market sale10b5-1 | 4,415 | $55.93 | $247K | 453,247 | Jul 28, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | open-market sale10b5-1indirect | 756 | $55.52 | $42K | 133,459 | Jul 28, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | open-market sale10b5-1indirect | 244 | $55.96 | $14K | 133,215 | Jul 28, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | open-market sale10b5-1indirect | 622 | $55.54 | $35K | 133,593 | Jul 28, 2026 |
| Jul 27, 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | open-market sale10b5-1indirect | 378 | $55.91 | $21K | 133,215 | Jul 28, 2026 |
| Jul 6, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | option exercise | 10,000 | $5.35 | $54K | 114,395 | Jul 6, 2026 |
| Jul 6, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | open-market sale10b5-1 | 7,913 | $57.16 | $452K | 106,482 | Jul 6, 2026 |
| Jul 6, 2026 | Guggenhime Andrew | PRESIDENT AND CFO | open-market sale10b5-1 | 2,087 | $57.76 | $121K | 104,395 | Jul 6, 2026 |
| Jul 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | option exercise | 516 | $5.35 | $3K | 159,010 | Jul 6, 2026 |
| Jul 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | open-market sale10b5-1 | 1,788 | $56.03 | $100K | 157,222 | Jul 6, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Pickering Grant | CHIEF EXECUTIVE OFFICER, Director | Sep 8, 2026 | tax withholding | 429,902 | — | $4M (18) | 18 of 18 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Oct 5, 2026 | option exercise | 163,435 | — | $3M (21) | 15 of 21 |
| Cowan Elvia | SVP, Finance & CAO | Oct 5, 2026 | option exercise | 46,860 | — | $3M (7) | 5 of 7 |
| Guggenhime Andrew | PRESIDENT AND CFO | Sep 8, 2026 | tax withholding | 95,316 | — | $2M (5) | 5 of 5 |
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | Sep 8, 2026 | tax withholding | 68,085 | — | $1M (2) | 1 of 2 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | Mar 5, 2025 | open-market sale | 41,620 | — | — | — |
| Loxam Teri | Director | Jun 15, 2026 | award | 12,481 | — | — | — |
| Paya Carlos V | Director | Jun 15, 2026 | award | 6,856 | — | — | — |
| Lukatch Heath | Director | Jun 15, 2026 | award | 19,481 | — | — | — |
| Brandicourt Olivier | Director | Jun 15, 2026 | award | 4,699 | — | — | — |
| Furey John | Director | Jun 15, 2026 | award | 5,306 | — | — | — |
| Lee Jacks | Director | Jun 15, 2026 | award | 6,856 | — | — | — |
| Gilbert Halley E | Director | Jun 15, 2026 | award | 12,481 | — | — | — |
| Drapeau Anne S | Director | Jun 15, 2026 | award | 12,481 | — | — | — |
| Jodar Luis | Chief Medical Officer | Sep 4, 2026 | award | 52,632 | — | — | — |
Questions
Are Vaxcyte, Inc. Common Stock insiders buying or selling?
Over the twelve months to November 3, 2026, 5 insiders at Vaxcyte, Inc. Common Stock sold $12M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $12M. Only open-market purchases and sales are counted.
Who sold the most Vaxcyte, Inc. Common Stock stock in the last year?
Pickering Grant (CHIEF EXECUTIVE OFFICER, Director) sold $4M in 18 open-market sales over the twelve months to November 3, 2026.
Do Vaxcyte, Inc. Common Stock executives sell under 10b5-1 plans?
44 of the 53 open-market sales in the last twelve months (83%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Vaxcyte, Inc. Common Stock
- Vaxcyte, Inc. Common Stock financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.